BIOCRYST PHARMACEUTICALS INC Uncategorized Contracts & Agreements

75 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2023
Drug/Drug Candidate
BIOCRYST PHARMACEUTICALS INC
Biotechnology
DE
2023
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2022
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2022
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2022
Amendment, dated August 10, 2022, to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2022
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2022
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
DE
2022
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
DE
2022
EX-10.76 EX-10.101 EX-10.102 EX-10.103 EX-10.104 EX-21 EX-23 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101 EX-104
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2022
EX-10.72 EX-10.76 EX-10.101 EX-10.102 EX-10.103 EX-10.104 EX-21 EX-23 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101 EX-104
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2022
EX-10.14 EX-10.72 EX-10.76 EX-10.101 EX-10.102 EX-10.103 EX-10.104 EX-21 EX-23 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101 EX-104
BIOCRYST PHARMACEUTICALS INC
Biotechnology
DE
2022
Amendment, dated August 27, 2021, to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2021
Amendment, dated August 31, 2020, to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2020
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2020
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
DE
2020
Drug/Drug Candidate
BIOCRYST PHARMACEUTICALS INC
Biotechnology
NY
2020
Drug/Drug Candidate
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2020
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2019
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2019
Amendment dated as of September 23, 2019 to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2019
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
DE
2019
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
MD
2019
Financial Statements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
MD
2018
Financial Statements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2018
Financial Statements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2018
Financial Statements
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2018
Contract dated as of September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Centers for Disease Control and Prevention
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2018
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2018
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2017
13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS, IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2016
Statement of Work BioCryst Pharmaceuticals Contract HHSO100201500007C BCX4430 NDA Enabling CMC and Non-Clinical Toxicology Studies
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2016
Pursuant to 17 CFR 20.24b-2, confidential information has been omittedin places marked "***" and has been filed separately with the Securities and Exchange Commission pursuant to...
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2015
1. DEFINITIONS AND INTERPRETATION
BIOCRYST PHARMACEUTICALS INC
Biotechnology
NY
2015
Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked *** and has been filed separately with the Securities and Exchange Commission pursuant to a...
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2015
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2014
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2014
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2014
Cash and cash equivalents
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2014
Option/Increment Description
BIOCRYST PHARMACEUTICALS INC
Biotechnology
2014